Home > Publications database > Metabolomics profiling of visceral and abdominal subcutaneous adipose tissue in colorectal cancer patients: results from the ColoCare study. > print

001     157754
005     20240229123144.0
024 7 _ |a 10.1007/s10552-020-01312-1
|2 doi
024 7 _ |a pmid:32430684
|2 pmid
024 7 _ |a pmc:PMC7425810
|2 pmc
024 7 _ |a 0957-5243
|2 ISSN
024 7 _ |a 1573-7225
|2 ISSN
024 7 _ |a altmetric:82574575
|2 altmetric
037 _ _ |a DKFZ-2020-01791
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Ose, Jennifer
|b 0
245 _ _ |a Metabolomics profiling of visceral and abdominal subcutaneous adipose tissue in colorectal cancer patients: results from the ColoCare study.
260 _ _ |a Dordrecht [u.a.]
|c 2020
|b Springer Science + Business Media B.V.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1599118402_16185
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Underlying mechanisms of the relationship between body fatness and colorectal cancer remain unclear. This study investigated associations of circulating metabolites with visceral (VFA), abdominal subcutaneous (SFA), and total fat area (TFA) in colorectal cancer patients.Pre-surgery plasma samples from 212 patients (stage I-IV) from the ColoCare Study were used to perform targeted metabolomics. VFA, SFA, and TFA were quantified by computed tomography scans. Partial correlation and linear regression analyses of VFA, SFA, and TFA with metabolites were computed and corrected for multiple testing. Cox proportional hazards were used to assess 2-year survival.In patients with metastatic tumors, SFA and TFA were statistically significantly inversely associated with 16 glycerophospholipids (SFA: pFDR range 0.017-0.049; TFA: pFDR range 0.029-0.048), while VFA was not. Doubling of ten of the aforementioned glycerophospholipids was associated with increased risk of death in patients with metastatic tumors, but not in patients with non-metastatic tumors (phet range: 0.00044-0.049). Doubling of PC ae C34:0 was associated with ninefold increased risk of death in metastatic tumors (Hazard Ratio [HR], 9.05; 95% confidence interval [CI] 2.17-37.80); an inverse association was observed in non-metastatic tumors (HR 0.17; 95% CI 0.04-0.87; phet = 0.00044).These data provide initial evidence that glycerophospholipids in metastatic colorectal cancer are uniquely associated with subcutaneous adiposity, and may impact overall survival.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 2 |a Adiposity
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Body Mass Index
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: diagnostic imaging
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: metabolism
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: pathology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Intra-Abdominal Fat: diagnostic imaging
|2 MeSH
650 _ 2 |a Intra-Abdominal Fat: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Metabolomics
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neoplasm Staging
|2 MeSH
650 _ 2 |a Subcutaneous Fat, Abdominal: diagnostic imaging
|2 MeSH
650 _ 2 |a Subcutaneous Fat, Abdominal: metabolism
|2 MeSH
650 _ 2 |a Tomography, X-Ray Computed
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
700 1 _ |a Holowatyj, Andreana N
|b 1
700 1 _ |a Nattenmüller, Johanna
|b 2
700 1 _ |a Gigic, Biljana
|b 3
700 1 _ |a Lin, Tengda
|b 4
700 1 _ |a Himbert, Caroline
|b 5
700 1 _ |a Habermann, Nina
|b 6
700 1 _ |a Achaintre, David
|b 7
700 1 _ |a Scalbert, Augustin
|b 8
700 1 _ |a Keski-Rahkonen, Pekka
|b 9
700 1 _ |a Böhm, Jürgen
|b 10
700 1 _ |a Schrotz-King, Petra
|0 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
|b 11
|u dkfz
700 1 _ |a Schneider, Martin
|b 12
700 1 _ |a Ulrich, Alexis
|b 13
700 1 _ |a Kampman, Ellen
|b 14
700 1 _ |a Weijenberg, Matty
|b 15
700 1 _ |a Gsur, Andrea
|b 16
700 1 _ |a Ueland, Per-Magne
|b 17
700 1 _ |a Kauczor, Hans-Ulrich
|b 18
700 1 _ |a Ulrich, Cornelia M
|b 19
773 _ _ |a 10.1007/s10552-020-01312-1
|g Vol. 31, no. 8, p. 723 - 735
|0 PERI:(DE-600)1496544-6
|n 8
|p 723 - 735
|t Cancer causes & control
|v 31
|y 2020
|x 1573-7225
909 C O |o oai:inrepo02.dkfz.de:157754
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2020-01-16
|w ger
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2020-01-16
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2020-01-16
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER CAUSE CONTROL : 2018
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-01-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-16
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-01-16
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21